<abstract xmlns="http://www.w3.org/1999/xhtml">

<sec id="j_jvetres-2022-0033_s_005">
<h3>Introduction</h3>
<p>Enhancer of zeste homologue 2 (EZH2) is the human homologue of <italic>Drosophila zeste</italic> gene enhancer. The aim of this study was to determine the expression of EZH2 in canine mammary carcinomas (CMCs) and its relationship with clinicopathological features.</p></sec>
<sec id="j_jvetres-2022-0033_s_006">
<h3>Material and Methods</h3>
<p>The expression of EZH2 mRNA and protein in 53 CMC tissue and 8 normal mammary gland tissue samples was measured by quantitative real-time PCR and immunohistochemical staining assay, respectively. The relationship between EZH2 protein expression and clinicopathological features was analysed by χ2 test to further explore the clinical significance of EZH2 in CMCs.</p></sec>
<sec id="j_jvetres-2022-0033_s_007">
<h3>Results</h3>
<p>Compared with normal mammary gland tissues, EZH2 mRNA expressions were significantly increased in CMC tissues (P &lt; 0.01). Moreover, normal mammary glands did not express the EZH2 protein but carcinomic glands did, and expression increased in CMCs with high histological grades, especially in histological grade II (P &lt; 0.05). However, EZH2 expression was not related to age, tumour size, or metastasis (P > 0.05). The expression of EZH2 in one type of CMC was not significantly different from the expression in any other type (P > 0.05).</p></sec>
<sec id="j_jvetres-2022-0033_s_008">
<h3>Conclusion</h3>
<p>EZH2 is highly expressed in CMCs, indicating that it can be used as a molecular marker for early diagnosis, prognosis, or therapy of CMCs.</p></sec>
</abstract>

Introduction
Enhancer of zeste homologue 2 (EZH2) is the human homologue of Drosophila zeste gene enhancer. The aim of this study was to determine the expression of EZH2 in canine mammary carcinomas (CMCs) and its relationship with clinicopathological features.

Material and Methods
The expression of EZH2 mRNA and protein in 53 CMC tissue and 8 normal mammary gland tissue samples was measured by quantitative real-time PCR and immunohistochemical staining assay, respectively. The relationship between EZH2 protein expression and clinicopathological features was analysed by χ2 test to further explore the clinical significance of EZH2 in CMCs.

Results
Compared with normal mammary gland tissues, EZH2 mRNA expressions were significantly increased in CMC tissues (P < 0.01). Moreover, normal mammary glands did not express the EZH2 protein but carcinomic glands did, and expression increased in CMCs with high histological grades, especially in histological grade II (P < 0.05). However, EZH2 expression was not related to age, tumour size, or metastasis (P > 0.05). The expression of EZH2 in one type of CMC was not significantly different from the expression in any other type (P > 0.05).

Conclusion
EZH2 is highly expressed in CMCs, indicating that it can be used as a molecular marker for early diagnosis, prognosis, or therapy of CMCs.

Clinicopathological analysis of expression of enhancer of zeste homologue 2 in canine mammary carcinoma

Journal of Veterinary Research

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Introduction
Enhancer of zeste homologue 2 (EZH2) is the human homologue of Drosophila zeste gene enhancer. The aim of this study was to determine the expression of EZH2 in canine mammary carcinomas (CMCs) and its relationship with clinicopathological features.

Material and Methods
The expression of EZH2 mRNA and protein in 53 CMC tissue and 8 normal mammary gland tissue samples was measured by quantitative real-time PCR and immunohistochemical staining assay, respectively. The relationship between EZH2 protein expression and clinicopathological features was analysed by χ2 test to further explore the clinical significance of EZH2 in CMCs.

Results
Compared with normal mammary gland tissues, EZH2 mRNA expressions were significantly increased in CMC tissues (P  0.05). The expression of EZH2 in one type of CMC was not significantly different from the expression in any other type (P > 0.05).

Conclusion
EZH2 is highly expressed in CMCs, indicating that it can be used as a molecular marker for early diagnosis, prognosis, or therapy of CMCs.

Introduction
Enhancer of zeste homologue 2 (EZH2) is the human homologue of Drosophila zeste gene enhancer. The aim of this study was to determine the...

Characteristics	N	Expression of EZH2 protein（n）		P
		-	+
Age				0.836
＜10	18	8	12
≥10	35	15	20
Size (cm)				0.186
＜3	16	9	7
3–5cm	28	8	20
≥5	9	4	5
Histological grade				0.011
I	16	11	5
II	30	7	23
III	7	3	4
Metastatic state				0.424
Yes	12	4	8
No	41	19	22
Histological type				0.489
Infiltrating ductal carcinoma	41	12	25
Intraductal papillary carcinoma	6	4	2
Invasive micropapillary carcinoma	3	2	1
Ductal carcinoma in situ	3	1	2

Clinicopathological analysis of expression of enhancer of zeste homologue 2 in canine mammary carcinoma

Pubblicato online: 05 lug 2022

Pagine: 267 - 272

Ricevuto: 22 dic 2021

Accettato: 20 giu 2022

DOI: https://doi.org/10.2478/jvetres-2022-0033

Parole chiave
canine mammary carcinoma, EZH2, clinicopathological examination

© 2022 X. Ren et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Fig. 1

Fig. 2

Relationship between expression of EZH2 and clinicopathological factors in CMCs

Clinicopathological analysis of expression of enhancer of zeste homologue 2 in canine mammary carcinoma

Pubblicato online: 05 lug 2022

Pagine: 267 - 272

Ricevuto: 22 dic 2021

Accettato: 20 giu 2022

DOI: https://doi.org/10.2478/jvetres-2022-0033

Parole chiavecanine mammary carcinoma, EZH2, clinicopathological examination

© 2022 X. Ren et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Fig. 1

Fig. 2

Relationship between expression of EZH2 and clinicopathological factors in CMCs

Parole chiave
canine mammary carcinoma, EZH2, clinicopathological examination